Prihlásiť sa Zaregistrujte sa zadarmo

EBITDA margin spoločnosti ProMIS Neurosciences

Aká je hodnota metriky EBITDA margin spoločnosti ProMIS Neurosciences?

Hodnota metriky EBITDA margin spoločnosti ProMIS Neurosciences, Inc. je -175,931.75%

Aká je definícia metriky EBITDA margin?



EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.

ttm (trailing twelve months)

EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.

EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.

EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.

EBITDA margin spoločností v sektore Health Care sektor na TSX v porovnaní so spoločnosťou ProMIS Neurosciences

Čomu sa venuje spoločnosť ProMIS Neurosciences?

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Firmy s metrikou ebitda margin podobnou spoločnosti ProMIS Neurosciences



  • Hodnota metriky EBITDA margin spoločnosti Indosolar je -213,170.97%
  • Hodnota metriky EBITDA margin spoločnosti Torrens Mining je -209,180.39%
  • Hodnota metriky EBITDA margin spoločnosti Roadman Investments je -198,529.94%
  • Hodnota metriky EBITDA margin spoločnosti Gett Gold Inc je -195,481.64%
  • Hodnota metriky EBITDA margin spoločnosti IMV je -190,473.91%
  • Hodnota metriky EBITDA margin spoločnosti Graphex Mining je -188,798.26%
  • Hodnota metriky EBITDA margin spoločnosti ProMIS Neurosciences je -175,931.75%
  • Hodnota metriky EBITDA margin spoločnosti Auroch Minerals je -172,893.76%
  • Hodnota metriky EBITDA margin spoločnosti Peak Resources je -170,548.84%
  • Hodnota metriky EBITDA margin spoločnosti Property Connect je -163,310.80%
  • Hodnota metriky EBITDA margin spoločnosti IPB Petroleum je -155,607.53%
  • Hodnota metriky EBITDA margin spoločnosti NorZinc je -151,270.00%
  • Hodnota metriky EBITDA margin spoločnosti Altur Investissement SCA je -145,911.00%